SARS-CoV-2 and miRNA-like inhibition power
Jacques Demongeot1*, Hervé Seligmann1,2
1

Laboratory AGEIS EA 7407, Team Tools for e-Gnosis Medical & Labcom CNRS/UGA/OrangeLabs
Telecom4Health, Faculty of Medicine, University Grenoble Alpes (UGA), 38700 La Tronche, France;
Jacques.Demongeot@univ-grenoble-alpes.fr

2

The National Natural History Collections, The Hebrew University of Jerusalem, 91404 Jerusalem,
Israel; varanuseremius@gmail.com

* Correspondence: Jacques.Demongeot@univ-grenoble-alpes.fr

Abstract: (1) Background: RNA viruses and especially coronaviruses could act inside host cells not
only by building their own proteins, but also by perturbing the cell metabolism. We show the
possibility of miRNA-like inhibitions by the SARS-CoV-2 concerning for example the hemoglobin
and type I interferons syntheses, hence highly perturbing oxygen distribution in vital organs and
immune response as described by clinicians; (2) Methods: We compare RNA subsequences of SARSCoV-2 protein S and RNA-dependent RNA polymerase genes to mRNA sequences of beta-globin
and type I interferons; (3) Results: RNA subsequences longer than eight nucleotides from SARSCoV-2 genome could hybridize subsequences of the mRNA of beta-globin and of type I interferons;
(4) Conclusions: Beyond viral protein production, Covid-19 might affect vital processes like host
oxygen transport and immune response.
Keywords: SARS-CoV-2; microRNA-like inhibition; oxygen metabolism; beta-globin translation
inhibition; type I interferons translation inhibition.
1. Introduction
Viruses act in host cells by reproducing their own proteins for reconstituting their capsid,
duplicating their genome [1] and leaving non-coding RNA or DNA remnants in host genomes [2].
Moreover, RNA viruses can also form complexes with existing mRNAs and/or proteins of host cells.
Thereby they might prevent protein function, behave like microRNAs [3-6] or ribosomal RNAs [6-8],
inhibiting or favoring the translation of specific proteins of host cells [9-17]. If these proteins are vital
for the host, viral pathogenicity is much greater than that caused by viral replication. With regard to
SARS-CoV-2, binding to existing host proteins has already been described [18]. Here, we aim to
describe a potential miRNA-like action by viral RNA, in particular i) at the level of oxygen transport
by hemoglobin, whose beta-globin and gamma 2 subunits synthesis can be inhibited, and ii) at the
level of immune response, where type I interferon synthesis can be inhibited. We are not intending
to prove here experimentally these inhibitions by small RNAs issued from the SARS-CoV-2 genome,
but to prepare this future empirical step by pointing out its potential hybridizing power. In Section
2, we describe a method for finding SARS-CoV-2 inhibitory RNA sub-sequences, and results are
given in Section 3, we discussed in Section 4. Some perspectives of this work concerning an extension
to the inhibition of translation of olfactory and interferon receptors are proposed in Section 5.
2. Methods
Focusing on the seed part of miRNA-like sequences having a putative 8 nucleotide
hybridization seed inhibition effect [19-20] (minimum 7), we compare data from different databases

[21-26] using BLAST [27]. Figure 1 shows microRNA 129-5p, a known inhibitor of a human foetal
hemoglobin component, the gamma-globin 2, replaced in adult by the beta-globin regulated as the
other component alpha-globin, by microRNAS [28-32]. Two sub-sequences from the SARS-CoV-2
genome, namely from genes of ORF10 and protein S, show the same hybridizing potential.
Homo sapiens hemoglobin subunit gamma 2 (HBG2), mRNA NCBI Reference Sequence: NM_000184.3
5’-ACACTCGCTTCTGGAACGTCTGAGGTTATCAATAAGCTCCTAGTCCAGACGCCATGGGTCATTTCACAGA
GGAGGACAAGGCTACTATCACAAGCCTGTGGGGCAAGGTGAATGTGGAAGATGCTGGAGGAGAAACCCTG
GGAAGGCTCCTGGTTGTCTACCCATGGACCCAGAGGTTCTTTGACAGCTTTGGCAACCTGTCCTCTGCCT
CTGCCATCATGGGCAACCCCAAAGTCAAGGCACATGGCAAGAAGGTGCTGACTTCCTTGGGAGATGCCAT
hsa-miR-129-5p 3’-TGTCGTTCGGGTCTGGC-5’
AAAGCACCTGGATGATCTCAAGGGCACCTTTGCCCAGCTGAGTGAACTGCACTGTGACAAGCTGCATGTG
GATCCTGAGAACTTCAAGCTCCTGGGAAATGTGCTGGTGACCGTTTTGGCAATCCATTTCGGCAAAGAAT
TCACCCCTGAGGTGCAGGCTTCCTGGCAGAAGATGGTGACTGGAGTGGCCAGTGCCCTGTCCTCCAGATA
protein S gene SARS-CoV-2 3’-CTGAAGTAGTGGAGATTAATGT-5’
CCACTGAGCTCACTGCCCATGATGCAGAGCTTTCAAGGATAGGCTTTATTCTGCAAGCAATCAAATAATA
ORF10 gene SARS-CoV-2 3’-TTCTAAGTAAGACGTGTTCTCATCTG-5’
AATCTATTCTGCTAAGAGATCACACA-3’

Figure 1. Complete mRNA sequence of the subunit gamma 2 of the fetal human hemoglobin [22].
Sequences in green (resp. red) come from protein S and ORF10 genes of SARS-CoV-2 (resp. hsa miR 1295p), which can inhibit its ribosomal translation. Probability of length 8 anti-match in red (resp. 9 and 11
in green) by chance in 577 nucleotides equals 0.035 (resp. 0.017 and 0.0003) (T-G and G-T matches
counting for ½).

3. Results
We will apply the method from Section 2 for showing examples where RNA subsequences of
the SARS-CoV-2 genome have an inhibitory potential on the ribosomal translation of human mRNAs
of the same type as that shown in Section 2 for human micro-RNAs. For example, miRTarBase shows
that microRNA hsa-mir-92a-3p targets the beta-globin HBB subunit of adult hemoglobin, inhibiting
its translation [25]. This is also the case for microRNas involved in the maturation of erythrocytes like
miR-451a [26-31]. We exhibit on Figure 2 subsequences of the SARS-CoV-2 protein S and polymerase
genes [23] having the same length of antimatching as these microRNAs on the mRNA of the
hemoglobin beta-globin (HBB) subunit gene.
Homo sapiens hemoglobin subunit beta (HBB), mRNA NCBI Reference Sequence: NM_000518.5
5’-ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACCATGGTGCATCTGACTCCTGAGGA
RNA-dependent RNA polymerase SARS-CoV-2

3’-TCACGTAGAACTAGGAGTATT-5’

GAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAGGCTG
CTGGTGGTCTACCCTTGGACCCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGG
GGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACCTGGACA
mir-451a

3’-TTGAGTCATTACCATTGCCAAA-5’

CCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGG
3’-TGTCCGGC
CTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGGCTG
CCTGTTCACGTTAT-5’ miR-92a-3p
CCTATCAGAAAGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGT
3’-ATTTTCACCTTTTACTACGCC-5’ Protein S SARS-CoV-2
CCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGA
GCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAA-3’

Figure 2. Human beta-globin gene [24] potentially targeted by a subsequence of the gene of the SARSCoV-2 RNA-dependent RNA polymerase (in blue) and by a subsequence of the gene of the SARSCoV-2 protein S (in green) [23], by the human microRNAs hsa miR 92a-3p (in red) and hsa miR 451a
(in red). Probability of red anti-matches of length 8 in a sequence of 624 nucleotides equals 0.04 and
for the blue (resp. green) subsequence is 0.005 (resp. 0.017) (T-G and G-T matches counting for ½).

The second example concerns the gene of the spicule protein S of SARS-CoV-2, which shares a
long subsequence of length 14 (664-678) with the gene of the Gag protein of the virus HERVK102 (Figure 3). Its potential targets are the mRNAs of human hemoglobin subunit beta-globin
[22], human hemoglobin subunit gamma-globin 2 (HBG2) [23], human type 1 interferons and
the human receptor ACE2.
SARS coronavirus 2 isolate USA/MN1-MDH1/2020, complete genome GenBank: MT188341.1: 21512-25333 protein S
5’-ATGTTTGTTTTTCTTGTTTTATTGCCACTAGTCTCTAGTCAGTGTGTTAATCTTACAACCAGAACTCAAT
TACCCCCTGCATACACTAATTCTTTCACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGT
TTTACATTCAACTCAGGACTTGTTCTTACCTTTCTTTTCCAATGTTACTTGGTTCCATGCTATACATGTC
TCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTTAATGATGGTGTTTATTTTGCTT
CCACTGAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCT
ACTTATTGTTAATAACGCTACTAATGTTGTTATTAAAGTCTGTGAATTTCAATTTTGTAATGATCCATTT
TTGGGTGTTTATTACCACAAAAACAACAAAAGTTGGATGGAAAGTGAGTTCAGAGTTTATTCTAGTGCGA
ATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGGAAAACAGGGTAATTTCAA
AAATCTTAGGGAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATT
AATTTAGTGCGTGATCTCCCTCAGGGTTTTTCGGCTTTAGAACCATTGGTAGATTTGCCAATAGGTATTA
ACATCACTAGGTTTCAAACTTTACTTGCTTTACATAGAAGTTATTTGACTCCTGGTGATTCTTCTTCAGG
TTGGACAGCTGGTGCTGCAGCTTATTATGTGGGTTATCTTCAACCTAGGACTTTTCTATTAAAATATAAT
GAAAATGGAACCATTACAGATGCTGTAGACTGTGCACTTGACCCTCTCTCAGAAACAAAGTGTACGTTGA
AATCCTTCACTGTAGAAAAAGGAATCTATCAAACTTCTAACTTTAGAGTCCAACCAACAGAATCTATTGT
TAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCCACCAGATTTGCATCTGTT
TATGCTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCAT
TTTCCACTTTTAAGTGTTATGGAGTGTCTCCTACTAAATTAAATGATCTCTGCTTTACTAATGTCTATGC
AGATTCATTTGTAATTAGAGGTGATGAAGTCAGACAAATCGCTCCAGGGCAAACTGGAAAGATTGCTGAT
TATAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTTGATTCTA
AGGTTGGTGGTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
TATTTCAACTGAAATCTATCAGGCCGGTAGCACACCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTT
CCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCATACAGAGTAGTAGTACTTT
CTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAAAAAGTCTACTAATTTGGTTAAAAACAA
ATGTGTCAATTTTAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCTG
CCTTTCCAACAATTTGGCAGAGACATTGCTGACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGA
TTCTTGACATTACACCATGTTCTTTTGGTGGTGTCAGTGTTATAACACCAGGAACAAATACTTCTAACCA
GGTTGCTGTTCTTTATCAGGATGTTAACTGCACAGAAGTCCCTGTTGCTATTCATGCAGATCAACTTACT
CCTACTTGGCGTGTTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGCTG
AACATGTCAACAACTCATATGAGTGTGACATACCCATTGGTGCAGGTATATGCGCTAGTTATCAGACTCA
GACTAATTCTCCTCGGCGGGCACGTAGTGTAGCTAGTCAATCCATCATTGCCTACACTATGTCACTTGGT
GCAGAAAATTCAGTTGCTTACTCTAATAACTCTATTGCCATACCCACAAATTTTACTATTAGTGTTACCA
CAGAAATTCTACCAGTGTCTATGACCAAGACATCAGTAGATTGTACAATGTACATTTGTGGTGATTCAAC
TGAATGCAGCAATCTTTTGTTGCAATATGGCAGTTTTTGTACACAATTAAACCGTGCTTTAACTGGAATA
GCTGTTGAACAAGACAAAAACACCCAAGAAGTTTTTGCACAAGTCAAACAAATTTACAAAACACCACCAA
TTAAAGATTTTGGTGGTTTTAATTTTTCACAAATATTACCAGATCCATCAAAACCAAGCAAGAGGTCATT
TATTGAAGATCTACTTTTCAACAAAGTGACACTTGCAGATGCTGGCTTCATCAAACAATATGGTGATTGC
CTTGGTGATATTGCTGCTAGAGACCTCATTTGTGCACAAAAGTTTAACGGCCTTACTGTTTTGCCACCTT
TGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGAC
CTTTGGTGCAGGTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGA
GTTACACAGAATGTTCTCTATGAGAACCAAAAATTGATTGCCAACCAATTTAATAGTGCTATTGGCAAAA
TTCAAGACTCACTTTCTTCCACAGCAAGTGCACTTGGAAAACTTCAAGATGTGGTCAACCAAAATGCACA
AGCTTTAAACACGCTTGTTAAACAACTTAGCTCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATC
CTTTCACGTCTTGACAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTT
TGCAGACATATGTGACTCAACAATTAATTAGAGCTGCAGAAATCAGAGCTTCTGCTAATCTTGCTGCTAC
TAAAATGTCAGAGTGTGTACTTGGACAATCAAAAAGAGTTGATTTTTGTGGAAAGGGCTATCATCTTATG
TCCTTCCCTCAGTCAGCACCTCATGGTGTAGTCTTCTTGCATGTGACTTATGTCCCTGCACAAGAAAAGA
ACTTCACAACTGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTC
AAATGGCACACACTGGTTTGTAACACAAAGGAATTTTTATGAACCACAAATCATTACTACAGACAACACA
TTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACACAGTTTATGATCCTTTGCAACCTG
AATTAGACTCATTCAAGGAGGAGTTAGATAAATATTTTAAGAATCATACATCACCAGATGTTGATTTAGG
TGACATCTCTGGCATTAATGCTTCAGTTGTAAACATTCAAAAAGAAATTGACCGCCTCAATGAGGTTGCC
AAGAATTTAAATGAATCTCTCATCGATCTCCAAGAACTTGGAAAGTATGAGCAGTATATAAAATGGCCAT
GGTACATTTGGCTAGGTTTTATAGCTGGCTTGATTGCCATAGTAATGGTGACAATTATGCTTTGCTGTAT
GACCAGTTGCTGTAGTTGTCTCAAGGGCTGTTGTTCTTGTGGATCCTGCTGCAAATTTGATGAAGACGAC
TCTGAGCCAGTGCTCAAAGGAGTCAAATTACATTACACATAA-3’

Figure 3. mRNA sequence of the protein S of the virus SARS-CoV-2 [23]. The first green subsequence
of length 14 (664-678) occurs in mRNA of Gag protein of the virus HERV-K102 [27]. The second of
length 23 (1112-1134) anti-matches a mRNA subsequence of hemoglobin subunit beta-globin [22].
The third of length 22 (1200-1221) anti-matches a mRNA subsequence of hemoglobin subunit
gamma-globin 2 (HBG2) [23]. The fourth of length 24 (2032-2055) matches a subsequence of mRNA
of many type 1 interferons. Highlighted in yellow are sub-sequences common with the SARS furin
cleavage site [33-34]. The fifth of length 25 (3152-3176) matches a subsequence of mRNA of the
receptor ACE2. Blue: mutations whose location of both codon and nucleotide involved [35] are, in
order: 635 gCtagTt, 1133 aAgaaGg, 2045 cGgacAg and 3189 ttG>ttT. The probabilities of the above
matches and anti-matches will be given in the following in Figures concerning each of them.
Homo sapiens ACE2 mRNA, complete cds GenBank: AB046569.1

5’-TTTTTAGTCTAGGGAAAGTCATTCAGTGGATGTGATCTTGGCTCACAGGGGACGATGTCAAGCTCTTCCT
GGCTCCTTCTCAGCCTTGTTGCTGTAACTGCTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATTTTT
GGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGCTTCTTGGAATTATAACACC
protein S SARS-CoV-2
3’-CTGTTTACCGTCCTCGTCAACACTT-5’
AATATTACTGAAGAGAATGTCCAAAACATGAATAACGCTGGGGACAAATGGTCTGCCTTTTTAAAGGAAC
AGTCCACACTTGCCCAAATGTATCCACTACAAGAAATTCAGAATCTCACAGTCAAGCTTCAGCTGCAGGC
TCTTCAGCAAAATGGGTCTTCAGTGCTCTCAGAAGACAAGAGCAAACGGTTGAACACAATTCTAAATACA
ATGAGCACCATCTACAGTACTGGAAAAGTTTGTAACCCAGATAATCCACAAGAATGCTTATTACTTGAAC
CAGGTTTGAATGAAATAATGGCAAACAGTTTAGACTACAATGAGAGGCTCTGGGCTTGGGAAAGCTGGAG
ATCTGAGGTCGGCAAGCAGCTGAGGCCATTATATGAAGAGTATGTGGTCTTGAAAAATGAGATGGCAAGA
GCAAATCATTATGAGGACTATGGGGATTATTGGAGAGGAGACTATGAAGTAAATGGGGTAGATGGCTATG
ACTACAGCCGCGGCCAGTTGATTGAAGATGTGGAACATACCTTTGAAGAGATTAAACCATTATATGAACA
TCTTCATGCCTATGTGAGGGCAAAGTTGATGAATGCCTATCCTTCCTATATCAGTCCAATTGGATGCCTC
CCTGCTCATTTGCTTGGTGATATGTGGGGTAGATTTTGGACAAATCTGTACTCTTTGACAGTTCCCTTTG
GACAGAAACCAAACATAGATGTTACTGATGCAATGGTGGACCAGGCCTGGGATGCACAGAGAATATTCAA
GGAGGCCGAGAAGTTCTTTGTATCTGTTGGTCTTCCTAATATGACTCAAGGATTCTGGGAAAATTCCATG
CTAACGGACCCAGGAAATGTTCAGAAAGCAGTCTGCCATCCCACAGCTTGGGACCTGGGGAAAGGCGACT
TCAGGATCCTTATGTGCACAAAGGTGACAATGGACGACTTCCTGACAGCTCATCATGAGATGGGGCATAT
TCAGTATGATATGGCATATGCTGCACAACCTTTTCTGCTAAGAAATGGAGCTAATGAAGGATTCCATGAA
GCTGTTGGGGAAATCATGTCACTTTCTGCAGCCACACCTAAGCATTTAAAATCCATTGGTCTTCTGTCAC
CCGATTTTCAAGAAGACAATGAAACAGAAATAAACTTCCTGCTCAAACAAGCACTCACGATTGTTGGGAC
TCTGCCATTTACTTACATGTTAGAGAAGTGGAGGTGGATGGTCTTTAAAGGGGAAATTCCCAAAGACCAG
TGGATGAAAAAGTGGTGGGAGATGAAGCGAGAGATAGTTGGGGTGGTGGAACCTGTGCCCCATGATGAAA
CATACTGTGACCCCGCATCTCTGTTCCATGTTTCTAATGATTACTCATTCATTCGATATTACACAAGGAC
CCTTTACCAATTCCAGTTTCAAGAAGCACTTTGTCAAGCAGCTAAACATGAAGGCCCTCTGCACAAATGT
GACATCTCAAACTCTACAGAAGCTGGACAGAAACTGTTCAATATGCTGAGGCTTGGAAAATCAGAACCCT
GGACCCTAGCATTGGAAAATGTTGTAGGAGCAAAGAACATGAATGTAAGGCCACTGCTCAACTACTTTGA
GCCCTTATTTACCTGGCTGAAAGACCAGAACAAGAATTCTTTTGTGGGATGGAGTACCGACTGGAGTCCA
TATGCAGACCAAAGCATCAAAGTGAGGATAAGCCTAAAATCAGCTCTTGGAGATAGAGCATATGAATGGA
ACGACAATGAAATGTACCTGTTCCGATCATCTGTTGCATATGCTATGAGGCAGTACTTTTTAAAAGTAAA
AAATCAGATGATTCTTTTTGGGGAGGAGGATGTGCGAGTGGCTAATTTGAAACCAAGAATCTCCTTTAAT
TTCTTTGTCACTGCACCTAAAAATGTGTCTGATATCATTCCTAGAACTGAAGTTGAAAAGGCCATCAGGA
TGTCCCGGAGCCGTATCAATGATGCTTTCCGTCTGAATGACAACAGCCTAGAGTTTCTGGGGATACAGCC
AACACTTGGACCTCCTAACCAGCCCCCTGTTTCCATATGGCTGATTGTTTTTGGAGTTGTGATGGGAGTG
ATAGTGGTTGGCATTGTCATCCTGATCTTCACTGGGATCAGAGATCGGAAGAAGAAAAATAAAGCAAGAA
GTGGAGAAAATCCTTATGCCTCCATCGATATTAGCAAAGGAGAAAATAATCCAGGATTCCAAAACACTGA
TGATGTTCAGACCTCCTTTTAGAAAAATCTATGTTTTTCCTCTTGAGGTGATTTTGTTGTATGTAAATGT
TAATTTCATGGTATAGAAAATATAAGATGATAAAAATATCATTAAATGTCAAAACTATGACTCTGTTCAG-3’
Figure 4. mRNA sequence of the human protein receptor ACE2. The green 5’-3’ seed subsequence of
length 10 is the reverse of an RNA sequence of the protein S of SARS-CoV-2. The probability to
observe such an anti-match of length 10 by chance in a sequence of 2581 nucleotides equals 0.003.

The classical protein-protein interaction of the spicule protein S of SARS-CoV-2 is with the human
protein receptor ACE2, but there exists a putative miRNA-like translation inhibition due to a

subsequence (in green) of the protein S gene (Figure 3) matching the ACE2 mRNA (Figure 4). The
human endogenous retrovirus HERV-K102 [32] has been described as having an antagonizing power
on HIV-1 replication, by stimulating antibody production. It is indeed capable of high replication rate
in vivo and in vitro and this high particle production can stimulate an early protective innate immune
response against HIV-1 replication. It could play the same role in SARS-CoV-2. A possible mechanism
of this immune stimulation could be due to the fact that both Gag protein of HERV-K107 and protein
S of SARS-CoV-2 share common sub-sequences as the subsequence of length 15 nucleotides from the
protein S of the SARS-CoV-2 given in green on Figure 5:
GCTTTAGAACCATTT
Homo sapiens endogenous retrovirus HERV-K102, complete sequence GenBank: AF164610.1: 1112-2596 Gag protein

5’-ATGGGGCAAACTAAAAGTAAAATTAAAAGTAAATATGCCTCTTATCTCAGCTTTATTAAAATTCTTTTAA
AAAGAGGGGGAGTTAAAGTATCTACAAAAAATCTAATCAAGCTATTTCAAATAATAGAACAATTTTGCCC
ATGGTTTCCAGAACAAGGAACTTTAGATCTAAAAGATTGGAAAAGAATTGGTAAGGAACTAAAACAAGCA
GGTAGGAAGGGTAATATCATTCCACTTACAGTATGGAATGATTGGGCCATTATTAAAGCAGCTTTAGAAC
CATTTCAAACAGAAGAAGATAGCGTTTCAGTTTCTGATGCCCTTGGAAGCTGTATAATAGATTGTAATGA
AAACACAAGGAAAAAATCCCAGAAAGAAACGGAAGGTTTACATTGCGAATATGTAGCAGAGCCGGTAATG
GCTCAGTCAACGCAAAATGTTGACTATAATCAATTACAGGAGGTGATATATCCTGAAACGTTAAAATTAG
AAGGAAAAGGTCCAGAATTAGTGGGGCCATCAGAGTCTAAACCACGAGGCACAAGTCATCTTCCAGCAGG
TCAGGTGCCCGTAACATTACAACCTCAAAAGCAGGTTAAAGAAAATAAGACCCAACCGCCAGTAGCCTAT
CAATACTGGCCTCCGGCTGAACTTCAGTATCGGCCACCCCCAGAAAGTCAGTATGGATATCCAGGAATGC
CCCCAGCACCACAGGGCAGGGCGCCATACCCTCAGCCGCCCACTAGGAGACTTAATCCTACGGCACCACC
TAGTAGACAGGGTAGTGAATTACATGAAATTATTGATAAATCAAGAAAGGAAGGAGATACTGAGGCATGG
CAATTCCCAGTAACGTTAGAACCGATGCCACCTGGAGAAGGAGCCCAAGAGGGAGAGCCTCCCACAGTTG
AGGCCAGATACAAGTCTTTTTCGATAAAAATGCTAAAAGATATGAAAGAGGGAGTAAAACAGTATGGACC
CAACTCCCCTTATATGAGGACATTATTAGATTCCATTGCTCATGGACATAGACTCATTCCTTATGATTGG
GAGATTCTGGCAAAATCGTCTCTCTCACCCTCTCAATTTTTACAATTTAAGACTTGGTGGATTGATGGGG
TACAAGAACAGGTCCGAAGAAATAGGGCTGCCAATCCTCCAGTTAACATAGATGCAGATCAACTATTAGG
AATAGGTCAAAATTGGAGTACTATTAGTCAACAAGCATTAATGCAAAATGAGGCCATTGAGCAAGTTAGA
GCTATCTGCCTTAGAGCCTGGGAAAAAATCCAAGACCCAGGAAGTACCTGCCCCTCATTTAATACAGTAA
GACAAGGTTCAAAAGAGCCCTATCCTGATTTTGTGGCAAGGCTCCAAGATGTTGCTCAAAAGTCAATTGC
CGATGAAAAAGCCCGTAAGGTCATAGTGGAGTTGATGGCATATGAAAACGCCAATCCTGATGTCAATCAG
CCATTAAGCCATTAA-3’
Figure 5. Complete RNA sequence of the Gag protein of the virus HERV-K102 [36]. The green
subsequence of length 14 (271-285) is present in the RNA sequence of the protein S of virus SARSCoV-2 [22]. The probability to observe this match of length 14 by chance in a sequence of 1475
nucleotides equals 10-6.

4. Discussion
When we combine the antibody power originated by the endogenous human retrovirus HERVK102 envelop protein (whose part of its mRNA is shared by the SARS-CoV-2 protein S [36]) with the
putative inhibitory role of circRNAs capable to block the miRNA-like action of SARS-CoV-2, one
could understand why certain carriers of SARS-CoV-2 are completely asymptomatic and therefore,
by mimicking their defence mechanisms, consider a possible therapy against SARS-CoV-2. Indeed, if
we look on the “sponge effect” of circRNAs against microRNAs [37-39], one can consider a
therapeutic effect erasing pathogenic actions of microRNAs.
For example, in the case of the human let-7e microRNA, a sub-sequence of human circular RNA PVT1
hybridizes hsa-let-7e (Figure 6), thus preventing it from exerting a too important inhibition on the
translation of proteins such as the gamma-globin 2. There exists a sub-sequence of the protein S of
SARS-CoV-2 (Figure 6), on which a similar action would be possible, hence reducing the miR-like

pathogenicity of the protein S, but with less efficiency, with a hybridization free energy ΔG equal to
-4.6 kcal/mol vs -11 for the hsa-let-7e.
Homo sapiens Pvt1 oncogene (PVT1), long non-coding RNA NCBI Reference Sequence: NR_003367.3

5’-CTCCGGGCAGAGCGCGTGTGGCGGCCGAGCACATGGGCCCGCGGGCCGGGCGGGCTCGGGGCGGCCGGGA
CGAGGAGGGGCGACGACGAGCTGCGAGCAAAGATGTGCCCCGGGACCCCCGGCACCTTCCAGTGGATTTC
CTTGCGGAAAGGATGTTGGCGGTCCCTGTGACCTGTGGAGACACGGCCAGATCTGCCCTCCAGCCTGATC
TTTTGGCCAGAAGGAGATTAAAAAGATGCCCCTCAAGATGGCTGTGCCTGTCAGCTGCATGGAGCTTCGT
TCAAGTATTTTCTGAGCCTGATGGATTTACAGTGATCTTCAGTGGTCTGGGGAATAACGCTGGTGGAACC
hsa-let-7e 3’-CCTTTCGATCCTCCG
ATGCACTGGAATGACACACGCCCGGCACATTTCAGGATACTAAAAGTGGTTTTAAGGGAGGCTGTGGCTG
GCAT-5’
AATGCCTCATGGATTCTTACAGCTTGGATGTCCATGGGGGACGAAGGACTGCAGCTGGCTGAGAGGGTTG
AGATCTCTGTTTACTTAGATCTCTGCCAACTTCCTTTGGGTCTCCCTATGGAATGTAAGACCCCGACTCT
TCCTGGTGAAGCATCTGATGCACGTTCCATCCGGCGCTCAGCTGGGCTTGAGCTGACCATACTCCCTGGA
GCCTTCTCCCGAGGTGCGCGGGTGACCTTGGCACATACAGCCATCATGATGGTACTTTAAGTGGAGGCTG
AATCATCTCCCCTTTGAGCTGCTTGGCACGTGGCTCCCTTGGTGTTCCCCTTTTACTGCCAGGACACTGA
GATTTGGAGAGAGTCTCACTCTGTGGTCCAGGCTGAAGTACAGTGGCATGATCCCAGGTCACTGCAACCC
3’-GTGAGGTATGTGAATTTTCACC-5’ Protein S SARS-CoV-2
CCACCTCCCGGGTTCAAGTGATCCTCCTGCCTCAGCCTCCCGAGTAGCTGGTATTACAGGCGTGTGCCAC-3’
Figure 6. RNA sub-sequence of the circPVT1 [22]. The RNA sequence in red is the microRNAs hsa miR
let-7 inhibited by its “sponge” hsa-circ-PVT1. The RNA sequence in green is a sub-sequence of the
protein S of SARS-CoV-2 on which hsa-circ-PVT1 could serve as inhibitor. Anti-match probability of a
sub-sequence of length 9 in a sequence of length 1946 is 0.06 (resp. 0.03) for the red (resp. green) subsequence.

We can also compare the putative miRNA-like inhibitory efficacy of the protein S in other
coronaviruses than SARS-CoV-2. By taking for example the SARS CoV Rs672 virus observed in 2006,
it is possible to exhibit in the RNA sequence of its protein S gene some sub-sequences similar to those
from SARS-CoV-2 involved in a miRNA inhibitory effect (Figure 7): they have less nucleotides antimatching their protein targets, which could explain lesser virulence of the SARS epidemic than of the
SARS-CoV-2 outbreak.
Bat SARS CoV Rs672/2006, complete genome GenBank: FJ588686.1: 20894-24619 protein S
5’-GATTGTGTTGCTGATTACACTGTTCTCTACAACTCAACTTCATTTTCAACTTTTAAATGTTATGGAGTTT
CTCCCTCTAAGTTGATTGACTTGTGCTTTACAAGTGTGTATGCTGATACATTCTTGATAAGATCTTCAGA
AGTAAGGCAAGTTGCACCAGGTGAAACTGGTGTTATTGCTGACTATAACTACAAACTGCCTGATGACTTT
ACAGGCTGTGTCATAGCTTGGAACACTGCTAAACAAGATCAGGGCCAGTATTATTATAGATCCTCCAGAA
AAACAAAACTTAAACCTTTTGAGAGGGATCTAACTTCTGACGAAAATGGTGTACGTACTCTTAGTACTTA
TGACTTCTATCCTAATGTGCCTATTGAATATCAGGCTACTAGGGTTGTTGTGCTTTCATTCGAGCTTCTA
AATGCACCTGCTACAGTTTGTGGACCTAAATTATCCACAGGACTTGTTAAGAACCAGTGTGTCAATTTCA
ATTTTAATGGACTCAAAGGTACTGGTGTTCTGACTGATTCTTCAAAGAGATTTCAGTCATTTCAACAATT
TGGAAGAGACACGTCGGATTTCACTGATTCCGTTCGTGACCCGCAAACATTGCAGATACTTGACATTACA
CCATGTTCTTTTGGTGGTGTGAGTGTAATAACACCTGGAACAAATGCTTCATCTGAAGTGGCTGTTCTTT
ACCAAGATGTAAACTGCACCGATGTCCCAACAGCCATACGTGCAGACCAATTAACACCAGCTTGGCGCGT
TTACTCAACCGGAGTAAATGTGTTTCAAACACAAGCTGGCTGTCTTATTGGAGCTGAACATGTTAACGCT
TCGTATGAGTGTGACATTCCTATTGGTGCTGGCATTTGTGCTAGCTACCATACAGCTTCTACTCTACGTA
GTGTAGGTCAGAAATCCATTGTGGCTTACACTATGTCTTTGGGTGCAGAAAATTCTATTGCTTATGCTAA-3’

Figure 7. RNA sub-sequence of the SARS CoV Rs672 protein S gene. Nucleotides in green are
homologous to those of SARS-CoV-2 protein S gene (in green on Figure 3), which could explain the
lesser virulence of SARS as compared to SARS-CoV-2 due to fewer anti-matches with their miRNAlike targets. The probability to observe by chance a sub-sequence of length 31 in a sequence of 3722
nucleotides with exactly 3 errors equals 3 C331 0.2531 = 3 10-15 and for a sub-sequence of length 11
equals 9 10-4.

Among the symptoms of the Covid-19 disease, anosmia is frequently described. This defect could be
due to a miRNA-like inhibition of mRNAs of genes from olfactory receptor family (Figure 8).
Homo sapiens olfactory receptor family 4 subfamily E member 1 (OR4E1), mRNA NCBI Reference Sequence: NM_001317107.1
5’-TTAAATGACCAAATGATTGATGCAGATACTGTGTTATATTAGACTTTTTTTCTAATTCTTTACAGGTTGT
CTAACAAAGAGAATGGAAGAGGCCATCCTACTCAATCAAACTTCTTTAGTGACATATTTTCGGCTTAGAG
GTTTATCTGTAAATCATAAGGCACGGATAGCTATGTTTTCCATGTTCCTCATTTTTTATGTCCTGACACT
GATTGGGAATGTTCTCATTGTCATAACTATTATCTATGACCACCGGCTCCATACTCCCATGTATTTCTTC
CTCAGCAACCTGTCCTTTATTGATGTCTGCCACTCCACTGTCACTGTCCCCAAGATGCTGAGAGACGTGT
GGTCAGAGGAAAAGCTCATCTCTTTTGATGCCTGTGTGACCCAGATGTTCTTCCTGCACCTCTTTGCCTG
CACAGAGATCTTCCTCCTCACCGTCATGGCCTATGATCGGTATGTGGCCATCTGTAAACCCCTGCAGTAC
ATGATAGTGATGAACTGGAAGGTATGTGTGCTGCTGGCTGTGGCCCTCTGGACAGGAGGGACCATCCACT
CCATAGCCCTCACCTCCCTTACCATCAAGCTGCCCTACTGTGGTCCTGATGAGATTGACAACTTCTTCTG
TGATGTACCTCAGGTGATCAAGCTGGCCTGCATTGACACCCACGTCATTGAGATCCTCATTGTCTCCAAC
AGTGGATTGATCTCCGTGGTCTGTTTTGTGGTCCTGGTGGTGTCCTACGCAGTCATCCTGGTGAGTCTGA
GGCAGCAGATCTCCAAGGGCAAGCGGAAGGCCCTGTCCACCTGTGCAGCCCATCTCACTGTAGTTACACT
3’-ATCGATGTGA
GTTCCTGGGACACTGCATCTTCATCTATTCCCGCCCATCCACCAGCCTCCCAGAGGACAAGGTAGTATCT
TGCACGGGCGG-5’
GTGTTTTTCACTGCAGTCACCCCCCTGCTGAACCCCATTATCTATACCCTTAGGAATGAAGAAATGAAGA
GTGCCTTAAACAAGTTAGTGGGGAGAAAAGAGAGAAAAGAAGAAAAATGAAAATGTCTACGTCCTTAGGA
TACGTGGTGCTCCAAATTAAAGAAGCGCCTTGCAAAGAATAAGTTACATACCATAT-3’

Figure 8. Complete mRNA sequence of the human olfactory receptor family 4 subfamily E member 1
(OR4E1) [22]. The RNA sequence in green is a sub-sequence of the protein S of SARS-CoV-2, which can
exert a miRNA-like inhibition of the translation of OR4E1. The probability to observe such an antimatch of length 12 by chance in a sequence of 577 nucleotides equals 5 10-4.

5. Perspectives
The perspectives of the present work are in the more in-depth study of unconventional
mechanisms of action of the SARS-CoV-2 virus, in particular those concerning the disturbances of
oxygen transport observed in many patients [41,42]. We can also notice the resemblance of a SARSCoV-2 sub-sequence with hsa-miR-let-7b, the microRNA the most upregulated in Kawasaki disease
[43] described as potentially linked to SARS-CoV-2 infection [44]. The SARS-CoV-2 virus could have,
more than a direct protein-protein interaction (proposed in [16] despite the criticisms of [45]), an
effective inhibitory action in vivo of the same type as that predicted here in silico on the synthesis of
subunits of human hemoglobin, and this action is more important for SARS-CoV-2 than for other
coronaviruses (like the SARS CoV Rs672 on Figure 8). This hypothesis is in agreement with numerous
studies showing a decrease of adult human hemoglobin blood concentrations in severe Covid-19
cases [46,47], presenting an increase of the high-sensitivity C-reactive protein as one of the three major
predictors of severity [48], like in ß-thalassemia [49] and viral infections [50]. Hence, one could
envisage a therapy blocking pathologic inhibitor effects on ribosomal translation of hemoglobin
subunits, using for example circular RNAs as blockers of possible viral miRNA-like mechanisms
(Figure 7) [51-54]. Another direction could be to search if furin cleavage site sub-sequence has the same
type of interaction with key proteins like Rac small GTPase (a protein from the Rho GTPase family,
which is a strong determinant of the virus-induced IFNbeta response [55-56]), implicated in
replication of many important viral pathogens infecting humans or like interferons. A first example
is given by the human small GTPase 1 (Figure 9) in which the inhibition of the SARS-CoV-2 protein
S gene is possibly obtained through the same miRNA-like subsequence as for all type 1 interferons.
The host immune system is indeed reacting to viral intrusion first with synthesis of type I interferons
IFNalphas and IFNbetas [57-58]. They are messengers allowing the activation of cellular defenses
blocking viral replication. In humans, these type I interferons are bound to interferon receptors, and
then, they induce proteins with antiviral actions: RNA-dependent protein kinase (PKR), 2′,5′oligoadenylate synthetase (OAS), RNase L, and Mx protein GTPases [59].

Homo sapiens Rac family small GTPase 1 (RAC1), transcript variant Rac1, mRNA NCBI Reference Sequence: NM_006908.5
5’-TAATGGAGTGAGCGTAGCAGCTCAGCTCTTTGGATCAGTCTTTGTGATTTCATAGCGAGTTTTCTGACCA
GCTTTTGCGGAGATTTTGAACAGAACTGCTATTTCCTCTAATGAAGAATTCTGTTTAGCTGTGGGTGTGC
TTTTTGTTACAGATTAATTTTTCCATAAAACCATTTTTTGAACCAATCAGTAATTTTAAGGTTTTGTTTG
TTCTAAATGTAAGAGTTCAGACTCACATTCTATTAAAATTTAGCCCTAAAATGACAAGCCTTCTTAAAGC
CTTATTTTTCAAAAGCGCCCCCCCCATTCTTGTTCAGATTAAGAGTTGCCAAAATACCTTCTGAACTACA
protein S SARS-CoV-2

3’-GATGT

CTGCATTGTTGTGCCGAGAACACCGAGCACTGAACTTTGCAAAGACCTTCGTCTTTGAGAAGACGGTAGC
GATGCACGGGCG-5’
TTCTGCAGTTAGGAGGTGCAGACACTTGCTCTCCTATGTAGTTCTCAGATGCGTAAAGCAGAACAGCCTC
CCGAATGAAGCGTTGCCATTGAACTCACCAGTGAGTTAGCAGCACGTGTTCCCGACATAACATTGTACTG
TAATGGAGTGAGCGTAGCAGCTCAGCTCTTTGGATCAGTCTTTGTGATTTCATAGCGAGTTTTCTGACCA
GCTTTTGCGGAGATTTTGAACAGAACTGCTATTTCCTCTAATGAAGAATTCTGTTTAGCTGTGGGTGTGC
CGGGTGGGGTGTGTGTGATCAAAGGACAAAGACAGTATTTTGACAAAATACGAAGTGGAGATTTACACTA
protein S SARS-CoV-2

3’-GATGTGAT

CATTGTACAAGGAATGAAAGTGTCACGGGTAAAAACTCTAAAAGGTTAATTTCTGTCAAATGCAGTAGAT
GATGCACG-5’
GATGAAAGAAAGGTTGGTATTATCAGGAAATGTTTTCTTAAGCTTTTCCTTTCTCTTACACCTGCCATGC
CTCCCCAAATTGGGCATTTAATTCATCTTTAAACTGGTTGTTCTGTTAGTCGCTAACTTAGTAAGTGCTT
TTCTTATAGAACCCCTTCTGACTGAGCAATATGCCTCCTTGTATTATAAAATCTTTCTGATAATGCATTA-3’

Figure 9. MiRNA-like subsequence of SARS-CoV-2 protein S gene (from its furin cleavage site) antimatching a subsequence of the human GTPase 1 gene. The probability to observe such anti-matches of
length 9 by chance in the of the 2301-length sequence of the whole human GTPase 1 gene equals 0.017.
Homo sapiens interferon alpha 7 (IFNA7), mRNA NCBI Reference Sequence: NM_021057.2
5’-TACCCACCTCAGGTAGCCTAGTGATATTTGCAAAATCCCAATGGCCCGGTCCTTTTCTTTACTGATGGTC
GTGCTGGTACTCAGCTACAAATCCATCTGCTCTCTGGGCTGTGATCTGCCTCAGACCCACAGCCTGCGTA
ATAGGAGGGCCTTGATACTCCTGGCACAAATGGGAAGAATCTCTCCTTTCTCCTGCTTGAAGGACAGACA
TGAATTCAGATTCCCAGAGGAGGAGTTTGATGGCCACCAGTTCCAGAAGACTCAAGCCATCTCTGTCCTC
CATGAGATGATCCAGCAGACCTTCAATCTCTTCAGCACAGAGGACTCATCTGCTGCTTGGGAACAGAGCC
TCCTAGAAAAATTTTCCACTGAACTTTACCAGCAACTGAATGACCTGGAAGCATGTGTGATACAGGAGGT
TGGGGTGGAAGAGACTCCCCTGATGAATGAGGACTTCATCCTGGCTGTGAGGAAATACTTCCAAAGAATC
hsa miR let-7b-5p 3’-CTTTGGTGTGTTG
ACTCTTTATCTAATGGAGAAGAAATACAGCCCTTGTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGAT
GATGATGGAG-5’

3’-TGCACGGGCGGCTCCTCTTAATC-5’ protein S SARS-CoV-2

CCTTCTCTTTTTCAACAAACTTGAAAAAAGGATTAAGGAGGAAGGATTGAAAACTGGTTCATCATGGAAA
TGATTCTCATTGACTAATGCATCATCTCACACTTTCATGAGTTCTTCCATTTCAAAGACTCACTTCTATA
ACCACCACAAGTTGAATCAAAATTTCCAAATGTTTTCCT-3’

Homo sapiens interferon regulatory factor 1 (IRF1), transcript variant 5, non-coding RNA NCBI RefSeq: NR_149069.2
5’-AGAGCTCGCCACTCCTTAGTCGAGGCAAGACGTGCGCCCGAGCCCCGCCGAACCGAGGCCACCCGGAGCC
GTGCCCAGTCCACGCCGGCCGTGCCCGGCGGCCTTAAGAACCCGGCAACCTCTGCCTTCTTCCCTCTTCC
3’-TGCACGGGCGGCTCCTCTTAAT-5’ protein S SARS-CoV-2
ACTCGGAGTCGCGCTCCGCGCGCCCTCACTGCAGCCCCTGCGTCGCCGGGACCCTCGCGCGCGACCGCCG
AATCGCTCCTGCAGCAGAGCCAACATGCCCATCACTCGGATGCGCATGAGACCCTGGCTAGAGATGCAGA
TTAATTCCAACCAAATCCCGGGGCTCATCTGGATTAATAAAGTGAGTGTAACTCTTTGGGTTTTCCTGCC
ACTGTTTTAACCCATGTACTTCTGGAGGGACCAAAGCTTCAGATGCAGCTCAAAAAGGGAAGTGATAACG
GGACAAGCAGGTGTTTCTCCCAGTGGGTCCTGCATGCAGGGAGTGTGCACGGCCCAGCCTGGGCCTCACT
3’-GTCTACGAAACTGTTATGATA-5’miRNA 301a-3p
TGCATGACTCCTGCCTTCTTCCCTTCTTGAGGTAGGGCACCCACCTGAAGGCACTTCCAGTTTCCAGCAG
CAAGACTTTCCAGCATCTGCAGAGCTGGAGTTCTGCTCTCCTCTAAGCGAGACCCTTACAAACATACACA
GCACTCTGCAGGGCTCCAATCGAACAAATAGAAGACTGAGAAGTGGATGCTGCTGGGCAGAAACGTGCCT
GGCTTAGCAGAGGACAAACGAGTTAATCTTGCACCAGTCACTCTGGCCCAAGAAGCCTATAGCTGGTGCA
CTTGGGGCAACATAGACCCTATAGACTTAGTAGCAATGATAGTATTCATAATAATAGCTAATGCTTACTG
AACACTCCCTGTGTGCCTGGCACCTGCTAAGTATGTTATTTACATTGTGTCATTTAATCCTCGCAGTAGT
3’-TGATGCACGGGCGGCTCCTCTT-5’ protein S SARS-CoV-2
CCTGTGGGTTAGATCTTACTAATGTCATCATTTTCAGATAAGTAAACAGAGGCACTGAGAGGTAGATCAT
AAGATCACACAAAAAGTGATGAAGCCAAGATTTGAACTTGAACGGTCTGACTCAGAAATCTT-3’

Figure 10. MiRNA-like subsequence of SARS-CoV-2 protein S gene (from its furin cleavage site) antimatching sequences from the human type 1 interferon (IFNA7) or interferon regulatory factor (IRF1).
In the first case, the sequence is the whole mRNA of IFNA7 and the probability to observe such an
anti-match of length 8 by chance in a sequence of 730 nucleotides equals 0.04. In the second case, the
sequence of the whole mRNA of IRF1 contains to targets and the probability to observe the last antimatch of length 11 by chance in a sequence of 1032 nucleotides equals 2 10-3. In red, miRNA inhibiting
sequences [59-60]. The probability to observe by chance the micro-RNA hsa miR let-7b-5p anti-match
of length 9 in the first 730-length sequence equals 0.02 and the micro-RNA hsa miR 301a-3p anti-match
of length 9 in the second 1032-length sequence equals 0.016.

In the same way, the miRNA-like subsequence of SARS-CoV-2 protein S gene from its furin cleavage
site) anti-matches the mRNA of the MCT1 gene involved in the lactate shuttle between astrocytes and
neurons (Figure 11) and this effect decreases the energy provided to the brain [61]. That could explain
some neurological and neuropsychiatric complications observed in SARS-COV-2 patients, since the
earliest cohorts featured non-specific neurological symptoms, such as dizziness and headache.
Homo sapiens clone peg2135 MCT1 (MCT1) mRNA, complete cds GenBank: AY364258.1
5’-ATGTTCAAGAAATTTGATGAAAAAGAAAATGTGTCCAACTGCATCCAGTTGAAAACTTCAGTTATTAAGG
GTATTAAGAATCAATTGATAGAGCAATTTCCAGGTATTGAACCATGGCTTAATCAAATCATGCCTAAGAA
hsa miR 342-5p 3’-GAGTTAGTGTCTATCGTGGG-5’
AGATCCTGTCAAAATAGTCCGATGCCATGAACATATAGAAATCCTTACAGTAAATGGAGAATTACTCTTT
TTTAGACAAAGAGAAGGGCCTTTTTATCCAACCCTAAGATTACTTCACAAATATCCTTTTATCCTGCCAC
ACCAGCAGGTTGATAAAGGAGCCATCAAATTTGTACTCAGTGGAGCAAATATCATGTGTCCAGGCTTAAC
TTCTCCTGGAGCTAAGCTTTACCCTGCTGCAGTAGATACCATTGTTGCTATCATGGCAGAAGGAAAACAG
CATGCTCTATGTGTTGGAGTCATGAAGATGTCTGCAGAAGACATTGAGAAAGTCAACAAAGGAATTGGCA
TTGAAAATATCCATTATTTAAATGATGGGCTGTGGCATATGAAGACATATAAATGAGCCTCAGAAGGAAT
GCACTTGGGCTAAATATGGATATTGTGCTGTATCTGTGTTTGTGTCTGTGTGTGACAGCATGAAGATAAT
protein S SARS-CoV-2 3’-TGCACGGGCGGCTCCTCTT-5’
GCCTGTGGTTATGCT G-3’

Figure 11. MiRNA-like subsequence of SARS-CoV-2 protein S gene (from its furin cleavage site) antimatching the mRNA of the human MCT1 gene. The probability to observe this anti-match of length 9
by chance in a sequence of 638 nucleotides equals 2.5 10-3. In red, the micro-RNA hsa miR 342-5p
inhibiting the human MCT1 gene sequence with a subsequence of length 8 and this anti-match has the
probability 0.02 to occur by chance in a sequence of 638 nucleotides.

Eventually, the mutations observed on SARS-CoV-2 [35, 63-64] can be neutral (without any effect),
favorable (less pathogenic) or deleterious (more pathogenic). Among them, we have (mutations in
red):
Neutral: Homo sapiens hemoglobin subunit gamma 2 (HBG2)
5’-GCTTTATTCTGCAAGCAA-3’
protein S SARS-CoV-2
3’-TGAGGTATTGTGGATTTT-5’
Homo sapiens Rac family small GTPase 1 (RAC1)
5’-CTGTGTGCCTGGCAC -3’
protein S SARS-CoV-2
3’-GATGCACGGGCGACT-5’
Favorable:
Homo sapiens ACE2 mRNA 5’-GACAAATGGTCTGCCTTTTTAAAGG-3’
protein S SARS-CoV-2 3’-CTTTTTACCGTCCTCGTCAACACTT-5’
Homo sapiens interferon regulatory factor 1 (IRF1) 5’-CCTGTGTGCCTGGCACCTGCTA -3’
protein S SARS-CoV-2 3’-TGATGCACGGGCGACTCCTCTT -5’
Deleterious:
Homo sapiens HERV-K102 Gag protein
5’-GCTTTAGAACCATTT-3’
protein S SARS-CoV-2
5’-GTTTTAGAACCATTT-3’
Homo sapiens hemoglobin betaglobin (HBB) 5’-TCAGAAAGTGGTGGCTGGTGTGG-3’
protein S SARS-CoV-2

3’-GGATTTTCACCTTTTACTACGCC-5’

We can notice also that the protein S gene is not the only SARS-CoV-2 gene anti-matching important
human molecules. It is for example the case of the ORF10 protein with the human gamma-globin 2
(Figure 12).

DNA at 37°C, CT = 0.00001 M

DNA at 37°C, CT = 0.00001 M

[Na+] = 1 M, [Mg++] = 0 M

[Na+] = 1 M, [Mg++] = 0 M

ΔG = -9.0 kcal/mol, ΔH = -85.9 kcal/mol

ΔG = -8.8 kcal/mol, ΔH = -66.3 kcal/mol

Figure 12. Hybridization between subsequences from SARS-CoV-2 genome and human genome. Left:
hybridization between a subsequence of the SARS-CoV-2 Protein S gene and a subsequence of the gene of
the human hemoglobin beta-globin (HBG) subunit (Figure 2). Right: hybridization between a subsequence
of the SARS-CoV-2 ORF10 gene and a subsequence of the gene of the human hemoglobin gamma-globin
2 (HGG 2) subunit (Figure 1).

On Figure 12, the free energy and enthalpy are given in kcal/mol for two hybridizations [65-66]
between subsequences of SARS-CoV-2 genes and subsequences of genes of two important proteins
of the human metabolism of oxygen, involved in the oxygen transportation in adult for the first (the
human hemoglobin beta-globin (HBG) subunit) and the in embryo for the second (the human
hemoglobin gamma-globin 2 (HGG 2) subunit).
We have summarized the probabilities of anti-matches of Figures 2 to 11 and in Table 1, allowing for
the comparison between the classical miRNA action and the putative inhibitory influence the protein
S gene of SARS-CoV-2 can have on the translation of important human proteins.

Table 1. Probability P and free energy ΔG (kcal/mol) of anti-matching between human genes and protein S gene subsequence
(TG and GT counting for ½).
Matching subsequence

Human/viral gene

P
3

ΔG

Fig.

10-15

protein S CTTCATTTTCAACTTTTAAATGTTATGGAGT

virus SARS CoV Rs672 Protein S

protein S GCTTTAGAACCATT

HERV-K102 protein Gag

10-6

7
5

hsa-miR-129-5p TGTCGTTC

human g-globin 2

0.035

-6.7

1

protein S CTGAAGTAG

human g-globin 2

0.017

-2.6

1

ORF10 AAGTAAGACGT

human g-globin 2

3 10

-8.8

1

RNA-dependent RNA polymerase ORF1ab

human beta-globin

5 10-3

-11.2

2

Anti-matching subsequence

-4

TCACGTAGAACTAGGAGTATT
miR 451a TGAGTCAT

human beta-globin

0.04

-3.2

2

protein S TTTTCACC

human beta-globin

0.017

-9

2

miR 92a-1-5p TGTCCGGC

human beta-globin

0.04

-8.2

2

protein S CTGTTTACCG

human ACE2

3 10-3

-9.5

4

protein S GTGAGGTAT

human circPVT1

0.03

-4.6

6

let-7e CCTTTCGAT

human circPVT1

0.06

-11

6

human olfactory receptor OR4E1

5 10-4

-7.7

8

protein S GATGTGATG

human GTPase 1

0.017

-6.8

9

let-7b-5p CTTTGGTGT

human type 1 interferon IFNA7

0.04

-3.2

10

protein S GCACGGGC

human type 1 interferon IFNA7

0.04

-10.7

10

protein S ATCGATGTGATG

miR 301a-3p GTCTACGAA

human type 1 interferon IRF1

0.016

-3.6

10

protein S GATGCACGGGC

human interferon regulatory factor

2 10-3

-8

10

IRF1
miR 342-5p GAGTTAGT

human MCT1

0.02

-3.9

11

protein S GCACGGGCG

human MCT1

2.5 10-3

-4

11

6. Conclusion
To conclude, the natural history of the SARS-CoV-2 virus remains widely unknown and it is still too
early to say whether the many mutations observed will cause it to evolve in a favorable direction
from a human point of view. There are for example some mutations surely deleterious [66,67], but
also others favoring the positive role of some human miRNAs against SARS-CoV-2 [68-70] suggesting
a possible therapy. The present proposal of a miRNA-like mechanism would at least allow to see, for
a predictive purpose, what mutations are keeping, losing or reinforcing its pathogenicity.

Author Contributions: Conceptualization, methodology, investigation, J.D.; resources, J.D.; data curation, J.D.;
writing—original draft preparation, J.D.; writing—review and editing, H.S. All authors have read and agreed to
the published version of the manuscript.
Funding: This research received no external funding
Conflicts of Interest: The authors declare no conflict of interest.

References
[1]

Demongeot J, Flet-Berliac Y, Seligmann H. Temperature decreases spread parameters of the new SARS-CoV-2

cases

dynamics. Biology (Basel) 2020; 9:94.
[2]

Demongeot J, Drouet E, Moreira A, Rechoum Y, Sené S. Micro-RNAs: viral genome and robustness of the genes
expression in host. Phil Trans Royal Soc A 2009; 367:4941-4965.

[3]

Bandiera S, Matégot R, Demongeot J, Henrion-Caude A. MitomiRs: delineating the intracellular localization of

[4]

Demongeot J, Hazgui H, Bandiera S, Cohen O, Henrion-Caude A. MitomiRs, ChloromiRs and general modelling of the

microRNAs at mitochondria. Free Radical in Biology and Medicine 2013; 64:12-19.
microRNA inhibition. Acta Biotheoretica 2013; 61:367-383.
[5]

Demongeot J, Cohen O, Henrion-Caude A. MicroRNAs and Robustness in Biological Regulatory Networks. A Generic
Approach with Applications at Different Levels: Physiologic, Metabolic, and Genetic. Springer Series in Biophysics 2013;
16:63-114.

[6]

Demongeot J, Hazgui H, Escoffier J, Arnoult C. Inhibitory regulation by microRNAs and circular RNAs. IFBME

[7]

Demongeot J, Henrion Caude A. The old and the new on the prebiotic conditions of the origin of life. Biology (Basel) 2020;

[8]

Demongeot J, Seligmann H. Comparisons between small ribosomal RNA and theoretical minimal RNA ring secondary

[9]

Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grässer FA, van Dyk LF, Ho CK, Shuman S, Chien M, Russo

Proceedings 2014; 41:722-725.
9:88.
structures confirm phylogenetic and structural accretion histories. Scientific Reports 2020; 10:7693.
JJ, Ju J, Randall G, Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan M, Tuschl T. Identification of microRNAs of the
herpesvirus family. Nat Methods 2005; 2:269–276.
[10]

Kincaid RP, Burke JM, Sullivan CS. RNA virus microRNA that mimics a B-cell oncomiR. Proc Natl Acad Sci USA 2012;
109:3077–3082.

[11]

Cullen BR. Viruses and microRNAs. Nat Genet 2006; 38:S25–S30.

[12]

Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004; 304:594-596.

[13]

Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol 2005; 3:e85.

[14]

Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics 2010; 11:537-561.

[15]

Li D, Dong H, Li S, Munir M, Chen J, Luo Y, Sun Y, Liu L, Qiu HJ. Hemoglobin subunit beta interacts with the capsid
protein and antagonizes the growth of classical swine fever virus. J Virol 2013; 87:5707-5717.

[16]

Liu W, Li H. SARS-COV-2 Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme
Metabolism. ChemRxiv Preprint 2020, https://doi.org/10.26434/chemrxiv.11938173.v5.

[17]

Sakuma T, Tonne JM, Squillace KA, Ohmine S, Thatava T, Peng KW, Barry MA, Ikeda Y. Early events in
retrovirus XMRV infection of the wild-derived mouse Mus pahari. J Virol 2011; 85:1205-1213.

[18]

Li X, Fu Z, Liang H, Wang Y, Qi X, Ding M, Sun X, Zhou Z, Huang Y, Gu H, Li L, Chen X, Li D, Zhao Q, Liu F, Wang H,
Wang J, Zen K, Zhang CY. H5N1 influenza virus-specific miRNA-like small RNA increases cytokine production and
mouse mortality via targeting poly(rC)-binding protein 2. Cell Res 2018; 28:157–171.

[19]

Wang X. Composition of seed sequence is a major determinant of microRNA targeting patterns. Bioinformatics 2014;
30:1377-1383.

[20]

Broughton JP, Lovci MT, Huang JL, Yeo GW, Pasquinelli AE. Pairing beyond the Seed Supports MicroRNA Targeting
Specificity. Mol Cell 2016; 64:320-333.

[21]

Nuccore. Available online: https://www.ncbi.nlm.nih.gov/nuccore/NR_029482.1?report=fasta (accessed on 8 May 2020).

[22]

Nuccore. Available online: https://www.ncbi.nlm.nih.gov/nuccore/MT446312.1?from=21561&to=25382& report=fasta
(accessed on 8 May 2020).

[23]

Nuccore. Available online: https://www.ncbi.nlm.nih.gov/nuccore/NM_000184.3?report=fasta (accessed on 8 May 2020).

[24]

Nuccore. Available online: https://www.ncbi.nlm.nih.gov/nuccore/NM_000518.5?report=fasta (accessed on 8 May 2020).

[25]

Genecards. Available online: https://www.genecards.org/cgi-bin/carddisp.pl?gene=HBB (accessed on 8 May 2020).

[26]

Mirbase. Available online: http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000093 (accessed on 8 May 2020).

[27] NCBI. Available online: https://www.ncbi.nlm.nih.gov/projects/msaviewer/?rid=BGU9FGPS114&coloring
(accessed on 8 May 2020).
[28]

Xu P, Palmer LE, Lechauve C, Zhao G, Yao Y, Luan J, Vourekas A, Tan H, Peng J, Schuetz JD, Mourelatos Z, Wu G,
Weiss MJ, Paralkar VR. Regulation of gene expression by miR-144/451 during mouse erythropoiesis. Blood 2019; 133:
2518–2528.

[29]

Wu C, Xue J, Dang X. Detection of miR-144 gene in peripheral blood of children with β-thalassemia major and its
significance. China Trop Med 2010; 10:285–286.

[30]

Saki N, Abroun S, Soleimani M, Kavianpour M, Shahjahani M, Mohammadi-Asl J, Hajizamani S. MicroRNA Expression
in β-Thalassemia and Sickle Cell Disease: A Role in The Induction of Fetal Hemoglobin. Cell J 2016; 17:583-592.

[31]

Lai K, Jia S, Yu S, Luo J, He Y. Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated coexpression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin. Oncotarget 2017;
8:49931-49943.

[32]

Alizadeh S, Kaviani S, Soleimani M, Kouhkan F, Pourfathollah AA, Amirizadeh N, Abroun S, Noruzinia M. Mir-155
downregulation by miRCURY LNA™ microRNA inhibitor can increase alpha chain hemoglobins expression in
erythroleukemic K562 cell line. Int J Hematol-Oncol Stem Cell Res 2010; 4:4-9.

[33]

Changeux JP, Amoura Z, Rey F, Miyara M. A nicotinic hypothesis for SARS-CoV-2 with preventive and therapeutic
implications. Comptes Rendus Biologies 2020; 343: 33-39.

[34]

Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell–cell fusion but
does not affect virion entry. Virology 2006; 350:358–369.

[35]
[36]

CNCB. Available online: https://bigd.big.ac.cn/ncov/variation/annotation/variant/24751 (accessed on 6 June 2020).
Laderoute MP, Larocque LJ, Giulivi A, Diaz-Mitoma F. Further Evidence that Human Endogenous RetroVirus K102 is
a Replication Competent Foamy Virus that may Antagonize HIV-1 Replication. Open AIDS J 2015; 9:112-122.

[37]

Holdt LM, Kohlmaier A, Teupser D. Circular RNAs as Therapeutic Agents and Targets. Frontiers Physiol 2018; 9:1262.

[38]

Wang M, Yu F, Wu W, Zhang Y, Chang W, Ponnusamy M, Wang K, Li P. Circular RNAs: A novel type of non-coding
RNA and their potential implications in antiviral immunity. Int J Biol Sci 2017; 13:1497-1506.

[39]

Panda AC, Grammatikakis I, Kim KM, De S, Martindale JL, Munk R, Yang X, Abdelmohsen K, Gorospe M. Identification
of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Research
2017; 45:4021–4035.

[40]

Ghetti M, Vannini I, Storlazzi CT, Martinelli G, Simonetti G. Linear and circular PVT1 in hematological malignancies
and immune response: two faces of the same coin. Mol Cancer 2020; 19:69.

[41] Geier MR, Geier DA. Respiratory conditions in coronavirus disease 2019 (SARS-COV-2): Important considerations
regarding novel treatment strategies to reduce mortality. Med Hypotheses 2020; 140:109760.
[42]

Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (SARS-COV-2): current status and future
perspectives. Int J Antimicrobial Agents 2020; 6:105951.

[43]

Chen Y, Ding YY, Ren Y, Cao L, Xu QQ, Sun L, Xu MG, Lv, HT. Identification of differentially expressed microRNAs in
acute Kawasaki disease. Molecular medicine reports 2018; 17:932–938.

[44]

Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Bradley Segal J, Nguyen, EL, Barsh GR, Maskatia S, Mathew R. SARSCOV-2 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr 2020; 10:537-540.

[45] Medium. Available online: https://medium.com/@amdahl/SARS-CoV-2-debunking-the-hemoglobin-story-ce27773d1096
(accessed on 25 May 2020).
[46]

Sun S, Cai X, Wang H, He G, Lin Y, Lu B, Chen C, Pan Y, Hu X. Abnormalities of peripheral blood system in patients
with SARS-COV-2 in Wenzhou, China. Clinica Chimica Acta 2020; 507:174–180.

[47]

Mardani R, Vasmehjani AA, Zali F, Gholami A, Nasab SDM, Kaghazian H, Kaviani M, Ahmadi N. Laboratory
Parameters in Detection of SARS-COV-2 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Archives of
Academic Emergency Medicine 2020; 8:e43.

[48]

Yan L, Zhang HT, Goncalves J, Xiao Y, Wang M, Guo Y, Sun C, Tang X, Jing L, Zhang M, Huang X, Xiao Y, Cao H, Chen
Y, Ren T, Wang F, Xiao Y, Huang S, Tan X, Huang N, Jiao B, Cheng C, Zhang Y, Luo A, Mombaerts L, Jin J, Cao Z, Li S,
Xu H, Yuan Y. An interpretable mortality prediction model for SARS-COV-2 patients. Nature Machine Intelligence 2020;
2:283–288.

[49]

Hassan TH, Elbehedy RM, Youssef DM, Amr GE. Protein C levels in β-thalassemia major patients in the east Nile delta
of Egypt. Hemat, Oncol & Stem Cell Therapy 2010; 3:60-65.

[50]

Lepik K, Annilo T, Kukuskina V, eQTLGen Consortium, Kisand K, Kutalik Z, Peterson P, Peterson H. C- reactive protein
upregulates the whole blood expression of CD59 - an integrative analysis. PLoS Comput Biol 2017; 13:e1005766.

[51]

Stower H. Circular sponges. Nat Rev Genet 2013; 14:238.

[52]

Zhang Q, Honko A, Zhou J, Gong H, Downs SN, Vasquez JH, Fang RH, Gao W, Griffiths A, Zhang L.
Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. Nano Letters 2020; 20:5570–5574.

[53]

Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides.
Silence 2012; 3:1.

[54]

Fleming SB. Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated
Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines 2016; 4:23.

[55]

Van den Broeke C, Jacob T, Favoreel, HW. Rho'ing in and out of cells: viral interactions with Rho GTPase signaling.
Small GTPases 2014; 5:e28318.

[56]
[57]

Spearman P. Viral interactions with host cell Rab GTPases. Small GTPases 2018; 9:192-201.
Hardy MP, Owczarek CM, Jermiin LS, Ejdebäck M, Hertzog PJ. Characterization of the type I interferon locus and
identification of novel genes. Genomics 2004; 84:331-345.

[58]

Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778-809.

[59]

Savan R. Post-transcriptional regulation of interferons and their signaling pathways. J. Interferon Cytokine Res 2014;
34:318-329.

[60]
[61]

miRBase. Available online: http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000063 (accessed on 6 June 2020).
Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin JL, Stella N, Magistretti PJ. Evidence supporting the
existence of an activity-dependent astrocyte-neuron lactate shuttle. Developmental Neuroscience 1998; 20:291–299.

[62]
[63]

miRBase. Available online: http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000805 (accessed on 6 June 2020).
Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, Easton A, Breen G, Zandi M, Coles
JP, Manji H, Salman RA, Menon DK, Nicholson TR, Benjamin LA, Carson A, Smith C, Turner MR, Solomon T, Kneen R,
Pett SL, Galea I, Thomas RH, Michael BD, on behalf of the CoroNerve Study Group. Neurological and neuropsychiatric
complications of SARS-COV-2 in 153 patients: a UK-wide surveillance study. The Lancet Psychiatry 2020;
doi.org/10.1016/S2215-0366(20)30287-X.

[64]

Unafold. Available online: http://unafold.rna.albany.edu/results2/twostate/200724/000229/ (accessed on 24 July 2020).

[65]

Unafold. Available online: http://unafold.rna.albany.edu/results2/twostate/200724/062836/ (accessed on 24 July 2020).

[66]

Yao H, Lu X, Chen Q, Xu K, Chen Y, Cheng L, Liu F, Wu Z, Wu H, Jin C, Zheng M, Wu N, Jiang C, Li L. Patient-derived
mutations

impact

pathogenicity

of

SARS-CoV-2.

MedRxiv

preprint

2020;

doi:

https://doi.org/10.1101/2020.04.14.20060160.
[67]

Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Foley B, Giorgi EE, Bhattacharya T, Parker MD,
Partridge DG, Evans CM, de Silva TI, LaBranche CC, Montefiori DC. Spike mutation pipeline reveals the emergence of
a more transmissible form of SARS-CoV-2. BioRxiv preprint 2020; doi: https://doi.org/10.1101/2020.04.29.069054.

[68]

Rakhmetullina A, Ivashchenko A, Akimniyazova A, Aisina D, Pyrkova A. The miRNA Complexes Against
Coronaviruses SARS-COV-2, SARS-CoV, And MERS-CoV. Research Square preprint 2020; DOI: 10.21203/rs.3.rs20476/v1.

[69]

Ivashchenko A, Rakhmetullina A, Aisina D. How miRNAs can protect humans from coronaviruses SARS-COV-2, SARSCoV, and MERS-CoV. Research Square preprint 2020; DOI: 10.21203/rs.3.rs-16264/v1.

[70]

Sadanand F, Bikash S, Ibrahim Y, Jin LT, Ashok S, Ravindra K, Isales CM. SARS-COV-2 Virulence in Aged Patients
Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile. Aging and Disease 2020 ; 11:509-522.

